PK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients

Starting soon

Conditions studied: Early Ventilator Associated Pneumonia, Acute Brain Injuries

In brief

Critically ill patients admitted for acute brain injury are exposed to many heath-care associated infections such as ventilator associated pneumoniae (VAP). The PROHYVAP study, published in 2024 reported that a single dose of CEFTRIAXONE as an antibiotic prophylaxis could reduce the incidence of early VAP (VAP that occured between day 2 and day 7 of mechanical ventilation). However, patients with acute brain injury also presented frequently augmented renal clearance (ARC), which could affect the pharmacokinetic and pharmacodynamic target attainment (PK/PD) of antibiotic prophylaxis. This study aims to analyse the PK/PD target attainment after one dose of CEFTRIAXONE in critically ill patients with acute brain injury and to describe the effect of ARC on PK/PD target attainment during early VAP.

Key facts

Study ID

NCT07450404

Run by

Central Hospital, Nancy, France

People needed

60

Starts

2026-03-01

Expected to finish

2027-10-01

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Admitted in intensive care unit for acute brain injury, including traumatic brain injury and cerebral vascular disease
• Glasgow coma scale inferior to 12
• Orotracheal intubation in first 12 hours of admission
• Needed of invasive mechanical ventilation for at least 48 hours

You may not qualify if…

• Acute brain injury related to tumoral or infectious process
• Antibiotic therapy administered before acute brain injury for an other pathology
• Patients with a risk of multiresistance bacteria contamination (stay in a risk area in the past 3 months, antibiotic therapy with fluoroquinolone or betalctamine in the past 3 months, hospitalization in last month before admission, documented contaminationwith multiresistance bacteria, immunodepression)
• Patients with hish risk of death in the first 48 hours
• Patients with a beta-lactams reported allergy

Where it is running

• CHRU de Nancy - Hôpital Central — Nancy, Lorraine, France
• CHRU Nancy - Hopital Central — Nancy, Meurthe-et-Moselle, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.